09688.HK
Zai Lab Limited
HKSE · Healthcare · Biotechnology · CN
HKD 20.76
−1.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 449.2M | 460.8M | 399.0M | 266.7M | 215.0M |
| Cost of Revenue | 195.5M | 191.4M | 147.9M | 95.8M | 74.0M |
| Gross Profit | 253.7M | 269.5M | 251.1M | 170.9M | 141.0M |
| Operating Expenses | |||||
| R&D Expense | 236.7M | 221.2M | 234.5M | 265.9M | 286.4M |
| SG&A Expense | 280.8M | 278.0M | 298.7M | 281.6M | 259.0M |
| General & Admin Expense | 252.3M | 277.6M | 298.7M | 281.6M | 259.0M |
| Selling & Marketing Expense | 28.8M | — | — | — | — |
| Other Expenses | — | — | — | (10.0M) | 3.1M |
| Total Operating Expenses | 517.5M | 499.2M | 533.2M | 537.5M | 545.4M |
| Cost and Expenses | 713.0M | 690.6M | 681.1M | 633.3M | 619.4M |
| Operating Income (EBIT) | (263.8M) | (229.8M) | (282.1M) | (366.6M) | (404.4M) |
| Non-Operating | |||||
| Interest Income | 27.9M | 33.1M | 37.1M | 39.8M | 14.6M |
| Interest Expense | 6.0M | 5.2M | 2.3M | — | — |
| Net Interest Income | 21.9M | 27.9M | 34.9M | 39.8M | 14.6M |
| Other Non-Op Income/Expense | 73.3M | 51.0M | 25.0M | 32.0M | (38.7M) |
| Non-Operating Income (excl Interest) | (40.5M) | — | (27.3M) | 7.6M | (11.5M) |
| EBT (Pre-Tax Income) | (190.5M) | (178.7M) | (257.1M) | (334.6M) | (443.1M) |
| Income Tax Expense | (2.5M) | (2.9M) | — | — | 38.9M |
| Bottom Line | |||||
| Net Income | (188.0M) | (175.8M) | (257.1M) | (334.6M) | (482.0M) |
| Earnings from Cont. Ops | (188.0M) | (175.8M) | (257.1M) | (334.6M) | (443.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (188.0M) | (175.8M) | (257.1M) | (334.6M) | (443.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.17) | (HK$0.16) | (HK$0.26) | (HK$3.46) | (HK$4.63) |
| Diluted EPS | (HK$0.17) | (HK$0.16) | (HK$0.26) | (HK$3.46) | (HK$4.63) |
| Revenue Per Share | HK$0.40 | HK$0.42 | HK$0.40 | HK$2.76 | HK$2.24 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 989.5M | 96.6M | 95.8M |
| Diluted Shares Outstanding | 1.1B | 1.1B | 989.5M | 96.6M | 95.8M |
| Profitability Metrics | |||||
| EBITDA | (204.1M) | (205.9M) | (243.0M) | (365.1M) | (384.7M) |
| D&A | 19.3M | 23.9M | 11.9M | 9.0M | 8.2M |
| EBIT | (223.3M) | (229.8M) | (254.8M) | (374.1M) | (392.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026